Board of Directors

Robert Cawthorn - Chairman of the Board

Robert Cawthorn has a unique and successful track record over 40 years in the pharmaceutical industry, which includes establishing start-ups and managing large pharmaceutical companies.

Following his retirement as Chairman and CEO of Rhône-Poulenc-Rorer, Inc., he was a managing director of Global Health Care Partners, DLJ Merchant Banking. After 17 years as an executive with Pfizer International, he became the first president of Biogen and was active in creating the foundations for the future success of that company. He joined the Rorer Group in 1982, and as Chairman and CEO, led the transformation of Rorer from a small, primarily over-the-counter pharmaceutical company into a major research-driven company, culminating in the merger that created Rhône-Poulenc-Rorer.

Robert is an investor in Actelion and Chairman of the Board of Directors.

Jean-Paul Clozel - CEO, Member of the Board, and Founder

Jean-Paul Clozel is a cardiologist educated in France, with further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco. After eleven years as a clinician, he decided to move to applied research. During his 12 years at F. Hoffmann-La Roche Ltd, he was responsible for the selection of the first T-channel blocker. He also participated in the characterization of renin inhibitors as well as several endothelin receptor antagonists such as bosentan and clazosentan. Overall, the group he was heading discovered seven compounds that entered clinical trials.

During his 25-year-career in cardiology, he has published widely in peer-reviewed medical and scientific journals. At the same time, his passion has remained unchanged: being involved as closely as possible in bringing innovative medicine to "his" patients. He has developed various, novel experimental models allowing the differentiation of these drugs, work honored with the 1997 Hoffmann-La Roche Research Prize. In 2007 he was nominated professor at the Collège de France in Paris, France (Chair of Technical Innovation).

At the end of 1997, Jean-Paul founded Actelion, together with his wife, Martine, and work colleagues and friends Walter Fischli, Thomas Widmann and André J. Mueller. First mainly focusing on Research and Development, he became CEO of the company to bring Actelion to the public in April 2000.

Juhani Anttila

Juhani Anttila studied law at the University of Helsinki, Finland before he became Managing Partner at CA Corporate Advisers, Zurich, in 1981.

Juhani was CEO of the Ascom Group between January 2003 and May 2004, and served as President and CEO of the Swisslog Group from 1996 to 2002. Between 1990 and 1995 he was Chairman of the Executive Board of Nokia (Deutschland) GmbH, Pforzheim. In 1985, Juhani was appointed Managing Director of Nokia GmbH, Zurich.

Carl Feldbaum

After receiving a bachelor's degree in biology from Princeton University and a law degree from the University of Pennsylvania Law School, Carl Feldbaum went to Washington D.C. in 1973 as an assistant special prosecutor for the Watergate special prosecution force.

Carl was president of the Biotechnology Industry Organization (BIO) in Washington, D.C. from its founding in 1993 to January 2005. Earlier roles concluded president and founder of the Palomar Corporation, a national security "think tank" in Washington, D.C. He also served as assistant to the Secretary of Energy and as the Inspector General for defense intelligence in the U.S. Department of Defense.

In 1979, Carl was awarded the Distinguished Civilian Service Medal by Defense Secretary Harold Brown.

Werner Henrich - Chairman of the Board of Basilea Pharmaceutica

Werner Henrich was born 1943 and is a French citizen. His educational background is as a chemist and European patent attorney.

Werner worked for F. Hoffmann-La Roche Ltd in Basel for more than 30 years, where he held various positions, including Head of Global Intellectual Property and Pharmaceutical Licensing for more than 12 years. He was also a member of the Roche Pharmaceutical Division Executive Board. In this capacity Werner was responsible for the intellectual property activities of all Roche divisions, and for major pharmaceutical transactions including research collaborations, patent settlements, licensing-in and -out, and product acquisitions. He retired from Roche in November 2003. Werner has wide experience in the pharmaceutical industry, both with start-ups and large pharmaceutical companies.

Werner is Chairman of the board of Basilea Pharmaceutica Ltd and a member of the board of directors of Actelion Ltd, Allschwil and Addex Pharmaceuticals Ltd, Geneva, Swiss biopharmaceutical companies listed on the SWX Swiss Exchange. He acts as a consultant for several biopharmaceutical companies on a part-time basis.

Michael Jacobi

Dr. Michael Jacobi, a German citizen, was Chief Financial Officer at Ciba Speciality Chemicals Inc. from 1996 until 2007. Michael joined the Ciba Group in 1978 and subsequently held various executive positions in the financial area in Switzerland, Brazil and the U.S.

Since 2003, Michael serves on the Board of Directors of Sonova Holding AG, formerly Phonak AG, since 2004 as the Head of the Audit Committee. Sonova, located in Staefa/Zurich, is a leading provider of innovative hearing healthcare solutions and the market leader in wireless communication systems for audiology applications. Furthermore, Michael serves on the Board of Directors of Hilti AG since 2007. Hilti, located in Schaan (Liechtenstein), provides leading-edge technology to the global construction industry. Since 2008, Michael is also a member of the Board of Trustees of the Martin Hilti Family Trust.

Michael received a PhD in Business Administration from the University of St. Gallen (HSG), St. Gallen, Switzerland, continued his studies at the University of Washington, Seattle, USA, and completed a Program for Management Development at Harvard Business School, Boston, USA.

Michael lives in Binningen, Switzerland.

Armin Kessler

Armin Kessler received a degree in Physics and Chemistry from Pretoria University in South Africa, a degree in Chemical Engineering from the University of Cape Town, South Africa, a Juris Doctorate from Seton Hall University, New Jersey, and Dr. h.c. in Business Administration from the University of Pretoria.

Armin served as Chief Operating Officer of F. Hoffmann-La Roche Ltd in Basel Switzerland from 1990 to 1995. Prior to being appointed COO, he held several senior positions at Roche, including head of the pharmaceutical and diagnostic divisions. Earlier positions in his career include Director of Pharmaceutical Marketing Worldwide for Sandoz (now Novartis), and President of Sandoz KK in Tokyo.

He currently serves on the board of The Medicines Company, Gen_Probe and Spectrum Pharmaceuticals (formerly Neotherapeutics) and has served on the boards of F. Hoffmann-La Roche, Syntex and Genentech.

Jean Malo - Chief Investment Officer of Breen Investors L.P.

Jean Malo received an MBA from Essec, Paris France, in 1977. He is a Chartered Financial Analyst, and a member of the Association for Investment Management and Research, and the Houston Society of Financial Analysts.

Jean joined Breen Investors L.P., a Houston-based investment advisor, as a Senior Partner and Chief Investment Officer, in 2000. He was Chief Investment Officer for Vaughan Nelson Scarborough and McCullough, a Houston-based affiliate of Metropolitan Life, managing $5 billion of assets between 1997 and 2000.

From 1989 to 1997, Jean managed both equity and fixed income portfolios for Daniel Breen and Company, an affiliate of Banque Indosuez (a French merchant bank), in Houston. From 1978 to 1989, he was a corporate banker for Banque Indosuez in Saudi Arabia, then in Houston, and finally in New York, where he was in charge of fixed income derivatives sales. Between 1977 and 1978, he was a financial analyst at the French Embassy in Singapore.

Joseph C. Scodari

Joseph C. Scodari, a citizen of the U.S., was Worldwide Chairman, Pharmaceuticals, member of the Executive Committee and Corporate Officer of Johnson & Johnson from February 2005 until March 2008. Joe joined Johnson & Johnson in 1999 as President of Centocor, Inc. when Johnson & Johnson acquired Centocor. At the time of that acquisition, he had been the President and Chief Operating Officer of Centocor and a member of Centocor's Board of Directors since December 1997. In 2001, he was named Company Group Chairman for the North American pharmaceutical business, and became a member of the Pharmaceuticals Group Operating Committee. In 2003, Joe was named Company Group Chairman, Global Biopharmaceutical Businesses.

Prior to his appointments at Centocor and Johnson & Johnson, Joe was Senior Vice President, General Manager – Americas at Rhone-Poulenc Rorer Pharmaceuticals Inc. and previously served in various executive positions at Rhone-Poulenc Rorer and Sterling Drug Inc.

From 2003 to 2007, Joe served on the Board of Directors of the Biotechnology Industry Organization (BIO) in Washington, D.C., and served as Vice-Chairman of the Board and Member of the Executive Committee from 2007 until February 2008. BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health care, agricultural, industrial and environmental biotechnology products.

Joe received a Bachelor's of Arts degree from Youngstown State University, Youngstown, Ohio, USA. He resides in Pennsylvania, USA.

Elias A. Zerhouni

Dr. Elias A. Zerhouni, a citizen of the U.S., served as Director of the US National Institutes of Health (NIH) from May 2002 until October 2008. He was nominated by the President of the United States in March 2002 and confirmed by the US Senate in April 2002.

From 1978 until 2002, Elias held various academic appointments at The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. In 1992, he was named Professor of Radiology at The Johns Hopkins University School of Medicine. In 1995, Elias was additionally appointed as Professor of Biomedical Engineering at The Johns Hopkins University. He became Director of the Russell H. Morgan Department of Radiology and Radiological Science at The Johns Hopkins University School of Medicine in 1996. Concurrently, he served as Executive Vice Dean, Vice Dean for Clinical Affairs and President of the Faculty Association at the Johns Hopkins University School of Medicine. From 1999 until 2002, he served as Executive Vice Dean and Vice Dean for Research at the Johns Hopkins University School of Medicine before being named to the directorship of the NIH.

Elias received a M.D. degree at the University of Algiers School of Medicine in Algeria in 1975 and continued his studies at the Department of Radiology at The Johns Hopkins University School of Medicine in Baltimore. He is the author of over 212 publications and holds 8 patents. Elias has received multiple awards and honours. He was elected to the Institute of Medicine of the US National Academy of Sciences in 2000.

Elias is currently a senior fellow at the Bill and Melinda Gates Foundation and has returned to his professorship at The Johns Hopkins University. He is a consultant and serves on multiple boards, such as the Lasker Foundation, the Mayo Clinic, Research America Board and the Board of the King Abdallah University of Sciences and Technology. He lives in Maryland, USA.